Pukateine

Pukateine

SCHEMBL674930

CN1CCc2cc3c(c4c2[C@H]1Cc1cccc(O)c1-4)OCO3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.74
LMNA P02545 2/20 0.74
DRD2 P14416 6/20 0.72
POLB P06746 2/20 0.72
CASP6 P55212 2/20 0.72
KMT2A Q03164 2/20 0.72
MEN1 O00255 1/20 0.72
APAF1 O14727 1/20 0.72
GAA P10253 1/20 0.72
RAB9A P51151 1/20 0.72
CASP7 P55210 1/20 0.72
DYRK1A Q13627 1/20 0.72
ADRA1D P25100 1/20 0.72
ADRA1A P35348 1/20 0.72
ADRA1B P35368 1/20 0.72
TDP1 Q9NUW8 1/20 0.72
BCHE P06276 2/20 0.70
ACHE P22303 2/20 0.70
SOST Q9BQB4 1/20 0.65
APP P05067 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pukateine SCHEMBL30373684 1.00 KDM4E (0.74) KDM4ELMNADRD2POLBCASP6
SCHEMBL11249690 0.85 DRD2 (0.76) KDM4ELMNADRD2POLBCASP6
SCHEMBL32690248 0.85 KDM4E (1.00) KDM4ELMNADRD2POLBCASP6
Roemerine SCHEMBL17906539 0.84 DRD2 (1.00) KDM4ELMNADRD2POLBCASP6
Roemerine SCHEMBL30047807 0.84 DRD2 (1.00) KDM4ELMNADRD2POLBCASP6
Roemerine SCHEMBL30047645 0.84 DRD2 (1.00) KDM4ELMNADRD2POLBCASP6
Roemerine SCHEMBL673805 0.84 DRD2 (1.00) KDM4ELMNADRD2POLBCASP6
Roemerine SCHEMBL678048 0.84 DRD2 (1.00) KDM4ELMNADRD2POLBCASP6
SCHEMBL25472589 0.82 BCHE (1.00) KDM4ELMNADRD2POLBCASP6
SCHEMBL15440507 0.81 KDM4E (0.69) KDM4ELMNADRD2POLBCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023121486-A1 COMPOSITIONS AND COMPOUNDS FOR TREATING COVID-19 INTERNATIONAL PATENT HOLDINGS LLC (KN) 2023-06-29 WO claimed
US-20210137854-A1 TAAR Receptor Agonists for the Treatment of Alopecia JUPITER WELLNESS INC. 2021-05-13 US claimed
WO-2020023084-A1 TAAR RECEPTOR AGONISTS FOR THE TREATMENT OF ALOPECIA APPLIED BIOLOGY, INC. (US) 2020-01-30 WO claimed
EP-3160553-A2 METHOD AND DEVICE FOR VAPORIZATION AND INHALATION OF ISOLATED SUBSTANCES Syqe Medical Ltd. (IL) 2017-05-03 EP claimed
WO-2016001921-A2 METHOD AND DEVICE FOR VAPORIZATION AND INHALATION OF ISOLATED SUBSTANCES SYQE MEDICAL LTD. (IL) 2016-01-07 WO claimed
US-8067401-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC (KN) 2011-11-29 US claimed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US claimed
EP-4079311-B1 NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM NUVAMID SA (CH) 2025-10-01 EP disclosed
US-20250170058-A1 METHOD AND DEVICE FOR VAPORIZATION AND INHALATION OF ISOLATED SUBSTANCES SYQE MEDICAL LTD. (IL) 2025-05-29 US disclosed
US-12201628-B2 Neuronal modulation TECHNION RESEARCH &DEVELOPMENT FOUNDATION LIMITED (IL) 2025-01-21 US disclosed
US-20240417421-A1 NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism NUVAMID SA (CH) 2024-12-19 US disclosed
US-20240352484-A1 REWARD SYSTEM ACTIVATION FOR THERAPEUTIC PURPOSES TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-10-24 US disclosed
WO-2024107708-A1 TAAR RECEPTOR AGONISTS FOR SEXUAL DYSFUNCTION ReJoy (US) 2024-05-23 WO disclosed
US-20120190734-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION INTERNATIONAL PATENT HOLDINGS LLC (KN) 2012-07-26 US disclosed
US-8067401-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC (KN) 2011-11-29 US disclosed
US-8067401-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC (KN) 2011-11-29 US disclosed
US-20100028469-A1 Extracts of Cranberry and Methods of Using Thereof HERBALSCIENCE GROUP, LLC (US) 2010-02-04 US disclosed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US disclosed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US disclosed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190734-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION RPN2, LSS, CLIC4 KDM4E 715/4885LMNA 4592/4885DRD2 252/4885
US-20090069277-A1 Compounds and compositions for treating infection RPN2, LSS, CLIC4 KDM4E 715/4885LMNA 4592/4885DRD2 252/4885
US-20240417421-A1 NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism SNCA, NLN, PARK7 KDM4E 4813/4885LMNA 173/4885DRD2 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.